Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 2/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375591 | 0.79 | ALDH1A1 (0.42) | ALDH1A1PDK2MAPT | |
| SCHEMBL5363504 | 0.77 | POLB (0.40) | ALDH1A1GAA | |
| SCHEMBL6902847 | 0.73 | NPC1 (0.40) | — | |
| SCHEMBL5370348 | 0.71 | POLB (0.46) | ALDH1A1 | |
| SCHEMBL5369331 | 0.71 | POLB (0.43) | ALDH1A1GAA | |
| SCHEMBL1231515 | 0.71 | APEX1 (0.45) | PDK2MAPTTHRBPTPRCMTNR1A | |
| SCHEMBL5645793 | 0.71 | OPRM1 (0.37) | ALDH1A1KDM4EGAAMTNR1AMTNR1B | |
| SCHEMBL14525409 | 0.70 | HSD11B1 (0.40) | ALDH1A1GAAMAPT | |
| SCHEMBL13548800 | 0.70 | LMNA (0.44) | KDM1APDK2 | |
| SCHEMBL5271185 | 0.69 | MTNR1A (0.47) | ALDH1A1KDM4EHSD17B10CFTRMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166616-B2 | Substituted alkanoic acids | AVENTIS PHARMA LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | AVENTIS PHARMA LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1330432-A2 | SUBSTITUTED ALKANOIC ACIDS | Aventis Pharma Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036553-A2 | SUBSTITUTED ALKANOIC ACIDS | AVENTIS PHARMA LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | VCAM1, LTB4R, ITGA1 | KDM1A 1862/4885ALDH1A1 354/4885KDM4E 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.